Nardin’s paper accepted

Nano, N., Ugwu, F., Seraphim, T. V., Li, T., Azer, G., Isaac, M., Prakesch, M., Barbosa, L. R. S., Ramos, C. H. I., Datti, A., & Houry, W. A. “Sorafenib as an Inhibitor of RUVBL2” Biomolecules 10(4), article number 605, 1-15; doi:10.3390/biom10040605 (2020). [Featured by OICR News https://news.oicr.on.ca/2020/05/study-points-to-common-protein-duo-as-a-new-therapeutic-target-for-several-cancer-types/